How to Rejuvenate Your Heart by 10 Years

Age catches up with us all eventually, but in some people the right genes can make that chase into our twilight years a relatively leisurely one.

A few years ago Italian researchers discovered something special about people who live well into their 90s and beyond: they commonly have a version of a gene called BPIFB4 that protects against cardiovascular damage and keeps the heart in good shape for a longer period of time.

By introducing the mutated gene into older mice, the scientists have now seen how the variant rewinds markers of biological heart aging by the equivalent of more than 10 human years.

In middle-aged mice, the same therapy was shown to halt the decline of heart function.

How quickly the heart and its nearest blood vessels typically decay depends on numerous factors, including how much we drink and whether or not we smoke. Based on the study's results, mutations in protein-encoding genes also have a key part to play.

The longevity-associated variant (LAV) of the BPIFB4 gene that the researchers looked at is already associated with longevity in people, and is frequently found in individuals who live longer than normal, including those in their late 90s and beyond. This finding prompted the researchers to take a closer look at the variant's physiological effects.

You must be logged in to view this content.

Early Stage Parkinson’s Disease Detected

The usual method of visualizing brain structure utilizes a technique most of us are familiar with, called MRI. However, it is not sensitive enough to reveal the biological changes that take place in the brain of Parkinson patients, and at present is primarily only used to eliminate other possible diagnoses.

The Hebrew University of Jerusalem (HU) researchers, led by Professor Aviv Mezer, realized that the cellular changes in Parkinson’s could possibly be revealed by adapting a related technique, known as quantitative MRI (qMRI). Their method has enabled them to look at microstructures within the part of the deep brain known as the striatum – an organ which is known to deteriorate during the progress of Parkinson’s disease. Using a novel method of analysis, developed by Mezer’s doctoral student, Elior Drori, biological changes in the cellar tissue of the striatum were clearly revealed. Moreover, they were able to demonstrate that these changes were associated with the early stages of Parkinson’s and patients’ movement dysfunction. Their findings were published 12 July 2022 in the prestigious journal Science Advances.

qMRI achieves its sensitivity by taking several MRI images using different excitation energies – rather like taking the same photograph in different colors of lighting. The HU researchers were able to use their qMRI analysis to reveal changes in the tissue structure within distinct regions of the striatum. The structural sensitivity of these measurements could only have been previously achieved in laboratories examining the brain cells of patients post mortem. Not an ideal situation for detecting early disease or monitoring the efficacy of a drug!

Description: MRI images used for automatic detection of microstructural changes in early-stage Parkinson’s Disease (PD) patients. Marked in yellow are areas in the putamen where PD patients show tissue damage, compared to healthy controls.

When you don’t have measurements, you don’t know what is normal and what is abnormal brain structure, and what is changing during the progress of the disease,” explained Mezer. The new information will facilitate early diagnosis of the disease and provide “markers” for monitoring the efficacy of future drug therapies. “What we have discovered,” he continued “is the tip of the iceberg.” It is a technique that they will now extend to investigate microstructural changes in other regions of the brain. Furthermore, the team are now developing qMRI into a tool that can be used in a clinical setting. Mezer anticipates that is about 3-5 years down the line.

Drori further suggests that this type of analysis will enable identification of subgroups within the population suffering from Parkinson’s disease – some of whom may respond differently to some drugs than others. Ultimately, he sees this analysis “leading to personalized treatment, allowing future discoveries of drug with each person receiving the most appropriate drug”.

Source: https://www.bfhu.org/

New Blood Test Could Replace Biopsies

No one enjoys getting a biopsy, in which a tissue sample is surgically taken and analyzed in a lab for signs of disease, such as cancer. It’s not only unpleasant for the patient, but has clinical drawbacks: A biopsy doesn’t always extract the diseased tissue and isn’t helpful in detecting disease at early stages. These concerns have encouraged researchers to find less invasive and more accurate diagnostic methods. Prof. Nir Friedman and Ronen Sadeh of the Hebrew University of Jerusalem have developed a blood test that enables lab technicians to diagnose cancer and diseases of the heart and liver by identifying and determining the state of the dead cells throughout the body.

Millions of cells die every day and are replaced by new cells. When cells die, their DNA is fragmented. Some of these DNA fragments reach the blood and can be “read” by advanced DNA sequencing methods.

As a result of these scientific advancements, we understood that if this information is maintained within the DNA structure in the blood, we could use that data to determine the tissue source of dead cells and the genes that were active in those very cells. Based on those findings, we can uncover key details about the patient’s health,” Friedman said.

We are able to better understand why the cells died — whether it’s an infection or cancer — and based on that, be better positioned to determine how the disease is developing,” he said. Co-author Israa Sharkia added the simple blood test could “be administered often and quickly, allowing the medical staff involved to follow the presence or development of a disease more closely.”

A startup company, Senseera, has been established to pursue clinical testing of this innovative approach in partnership with major pharmaceutical companies.

The multi-author study published in Nature Biotechnology explains the test can even identify markers that may differentiate between patients with similar tumors, which could help physicians develop personalized treatments.

Source: https://www.zenger.news/

Coronavirus Uses Same Strategy As HIV To Dodge Immune Response

The novel coronavirus uses the same strategy to evade attack from the human immune system as HIV, according to a new study by Chinese scientists.

Both viruses remove marker molecules on the surface of an infected cell that are used by the immune system to identify invaders, the researchers said in a non-peer reviewed paper posted on preprint website bioRxiv.org on Sunday. They warned that this commonality could mean Sars-CoV-2, the clinical name for the virus, could be around for some time, like HIV.

Virologist Zhang Hui and a team from Sun Yat-sen University in Guangzhou also said their discovery added weight to clinical observations that the coronavirus was showing “some characteristics of viruses causing chronic infection”.

Their research involved collecting killer T cells from five patients who had recently recovered from Covid-19, the disease caused by the virus. Those immune cells are generated by people after they are infected with Sars-CoV-2 – their job is to find and destroy the virus.

The molecule is an identification tag usually present in the membrane of a healthy cell, or in sick cells infected by other coronaviruses such as severe acute respiratory syndrome, or Sars. It changes with infections, alerting the immune system whether a cell is healthy or infected by a virusHIV uses the same strategyMHC molecules are also absent in cells infected with that virusIn contrast, Sars does not make use of this function,” Zhang said.

The coronavirus removes these markers by producing a protein known as ORF8, which binds with MHC molecules, then pulls them inside the infected cell and destroys them, the researchers said. ORF8 is known to play an important role in viral replication, and most commercial test kits target this gene to detect viral loads in nose or oral swabs.

While drugs being used to treat Covid-19 patients mainly targeted enzymes or structural proteins needed for viral replication, Zhang and his team suggested compounds be developedspecifically targeting the impairment of MHC by ORF8, and therefore enhancing immune surveillance for Sars-CoV-2 infection”.

Source: https://www.scmp.com/

How To Early Detect Prostate Cancer

For the first time, a team of scientists at the University of Central Florida has created functional nanomaterials with hollow interiors that can be used to create highly sensitive biosensors for early cancer detection. Xiaohu Xia, an assistant professor of chemistry with a joint appointment in the NanoScience Technology Center, and his team developed the new method and recently published their work in the journal ACS Nano.

These advanced hollow nanomaterials hold great potential to enable high-performance technologies in various areas,” says Xia. “Potentially we could be talking about a better and less expensive diagnostic tool, sensitive enough to detect biomarkers at low concentrations, which could make it invaluable for early detection of cancers and infectious diseases.”

Because hollow nanomaterials made of gold and silver alloys display superior optical properties, they could be particularly good for developing better test strip technology, similar to over-the-counter pregnancy tests. Currently the technology used to indicate positive or negative symbols on the test stick is not sensitive enough to pick up markers that indicate certain types of cancer. But Xia’s new method of creating hollow nanomaterials could change that. More advance warning could help doctors save more lives.

In conventional test strips, solid gold nanoparticles are often used as labels, where they are connected with antibodies and specifically generate color signal due to an optical phenomenon called localized surface plasmon resonance. Under Xia’s technique, metallic nanomaterials can be crafted with hollow interiors. Compared to the solid counterparts, these hollow nanostructures possess much stronger LSPR activities and thus offer more intense color signal. Therefore, when the hollow nanomaterials are used as labels in test strips they can induce sensitive color change, enabling the strips to detect biomarkers at lower concentrations.

Test-strip technology gets upgraded by simply replacing solid gold nanoparticles with the unique hollow nanoparticles, while all other components of a test strip are kept unchanged,” says Xia. “Just like the pregnancy test, the new test strip can be performed by non-skilled persons, and the results can be determined with the naked eye without the need of any equipment. These features make the strip extremely suitable for use in challenging locations such as remote villages.”

The UCF study focused on prostate-specific antigen, a biomarker for prostate cancer. The new test strip based on hollow nanomaterials was able to detect PSA as low as 0.1 nanogram per milliliter (ng/mL), which is sufficiently sensitive for clinical diagnostics of prostate cancer. The published study includes electron microscope images of the metallic hollow nanomaterials.

“I hope that by providing a general and versatile platform to engineer functional hollow nanomaterials with desired properties, new research with the potential for other applications beyond biosensing can be launched,” Xia says.

Source: https://www.ucf.edu/